These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 26096739)
1. Multivariate analysis as a method for evaluating the pathogenicity of novel genetic MLH1 variants in patients with colorectal cancer and microsatellite instability. Duraturo F; Liccardo R; Cavallo A; De Rosa M; Rossi GB; Izzo P Int J Mol Med; 2015 Aug; 36(2):511-7. PubMed ID: 26096739 [TBL] [Abstract][Full Text] [Related]
2. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines. Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M Tumori; 2014; 100(3):315-20. PubMed ID: 25076244 [TBL] [Abstract][Full Text] [Related]
3. Lynch syndrome-associated colorectal carcinoma: frequent involvement of the left colon and rectum and late-onset presentation supports a universal screening approach. Hartman DJ; Brand RE; Hu H; Bahary N; Dudley B; Chiosea SI; Nikiforova MN; Pai RK Hum Pathol; 2013 Nov; 44(11):2518-28. PubMed ID: 24034859 [TBL] [Abstract][Full Text] [Related]
4. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR. Bettstetter M; Dechant S; Ruemmele P; Grabowski M; Keller G; Holinski-Feder E; Hartmann A; Hofstaedter F; Dietmaier W Clin Cancer Res; 2007 Jun; 13(11):3221-8. PubMed ID: 17545526 [TBL] [Abstract][Full Text] [Related]
5. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055 [TBL] [Abstract][Full Text] [Related]
6. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Loughrey MB; Waring PM; Tan A; Trivett M; Kovalenko S; Beshay V; Young MA; McArthur G; Boussioutas A; Dobrovic A Fam Cancer; 2007; 6(3):301-10. PubMed ID: 17453358 [TBL] [Abstract][Full Text] [Related]
7. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer. Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581 [TBL] [Abstract][Full Text] [Related]
8. Taiwan hospital-based detection of Lynch syndrome distinguishes 2 types of microsatellite instabilities in colorectal cancers. Chang SC; Lin PC; Yang SH; Wang HS; Liang WY; Lin JK Surgery; 2010 May; 147(5):720-8. PubMed ID: 20045164 [TBL] [Abstract][Full Text] [Related]
9. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306 [TBL] [Abstract][Full Text] [Related]
10. Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features. Schiemann U; Müller-Koch Y; Gross M; Daum J; Lohse P; Baretton G; Muders M; Mussack T; Kopp R; Holinski-Feder E Digestion; 2004; 69(3):166-76. PubMed ID: 15118395 [TBL] [Abstract][Full Text] [Related]
12. Validation microsatellite path score in a population-based cohort of patients with colorectal cancer. Bessa X; Alenda C; Paya A; Álvarez C; Iglesias M; Seoane A; Dedeu JM; Abulí A; Ilzarbe L; Navarro G; Pellise M; Balaguer F; Castellvi-Bel S; Llor X; Castells A; Jover R; Andreu M J Clin Oncol; 2011 Sep; 29(25):3374-80. PubMed ID: 21788563 [TBL] [Abstract][Full Text] [Related]
13. Histologic features distinguish microsatellite-high from microsatellite-low and microsatellite-stable colorectal carcinomas, but do not differentiate germline mutations from methylation of the MLH1 promoter. Yearsley M; Hampel H; Lehman A; Nakagawa H; de la Chapelle A; Frankel WL Hum Pathol; 2006 Jul; 37(7):831-8. PubMed ID: 16784982 [TBL] [Abstract][Full Text] [Related]
14. The role of MLH1, MSH2 and MSH6 in the development of multiple colorectal cancers. Lawes DA; Pearson T; Sengupta S; Boulos PB Br J Cancer; 2005 Aug; 93(4):472-7. PubMed ID: 16106253 [TBL] [Abstract][Full Text] [Related]
15. Microsatellite instability, MLH1 promoter methylation, and BRAF mutation analysis in sporadic colorectal cancers of different ethnic groups in Israel. Vilkin A; Niv Y; Nagasaka T; Morgenstern S; Levi Z; Fireman Z; Fuerst F; Goel A; Boland CR Cancer; 2009 Feb; 115(4):760-9. PubMed ID: 19127559 [TBL] [Abstract][Full Text] [Related]
16. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency. Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842 [TBL] [Abstract][Full Text] [Related]
17. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. Parsons MT; Buchanan DD; Thompson B; Young JP; Spurdle AB J Med Genet; 2012 Mar; 49(3):151-7. PubMed ID: 22368298 [TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Poynter JN; Siegmund KD; Weisenberger DJ; Long TI; Thibodeau SN; Lindor N; Young J; Jenkins MA; Hopper JL; Baron JA; Buchanan D; Casey G; Levine AJ; Le Marchand L; Gallinger S; Bapat B; Potter JD; Newcomb PA; Haile RW; Laird PW; Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3208-15. PubMed ID: 18990764 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome. Tresallet C; Brouquet A; Julié C; Beauchet A; Vallot C; Ménégaux F; Mitry E; Radvanyi F; Malafosse R; Rougier P; Nordlinger B; Laurent-Puig P; Boileau C; Emile JF; Muti C; Penna C; Hofmann-Radvanyi H Int J Cancer; 2012 Mar; 130(6):1367-77. PubMed ID: 21520036 [TBL] [Abstract][Full Text] [Related]
20. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Pérez-Carbonell L; Ruiz-Ponte C; Guarinos C; Alenda C; Payá A; Brea A; Egoavil CM; Castillejo A; Barberá VM; Bessa X; Xicola RM; Rodríguez-Soler M; Sánchez-Fortún C; Acame N; Castellví-Bel S; Piñol V; Balaguer F; Bujanda L; De-Castro ML; Llor X; Andreu M; Carracedo A; Soto JL; Castells A; Jover R Gut; 2012 Jun; 61(6):865-72. PubMed ID: 21868491 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]